Brief: Pharmather Initiates Phase 2 Clinical Trial Of Ketamine For The Treatment Of Parkinson’s Disease
06/10/2021 14:12
Oct 6 (Reuters) - Pharmather Holdings Ltd PHRM.CD :
* PHARMATHER INITIATES PHASE 2 CLINICAL TRIAL OF KETAMINE
FOR THE
TREATMENT OF PARKINSON’S DISEASE
* PHARMATHER HOLDINGS LTD - PATIENT SCREENING AND ENROLLMENT
IS
EXPECTED TO BEGIN IN OCTOBER 2021 WITH DATA ANTICIPATED IN
LATE-Q4 2021
Source text for Eikon: ID:nGNX8cPbpj
Further company coverage: PHRM.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pharmather Holdings
See all newsBrief: Pharmather Sells Ketamine ANDA, Eyes Over $25M In Milestone And Profit-Sharing Payments
Brief: Pharmather receives US FDA approval goal date for Ketamine
Brief: Pharmather Announces Update On FDA New Drug Application For Ketamine
Brief: PharmTther Announces Post Complete Response Letter Clarification Meeting Request Granted From The FDA For Ketamine Abbreviated New Drug Application
Brief: Pharmather Receives Complete Response Letter From The U.S. Food And Drug Administration For Ketamine Abbreviated New Drug Application